目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.4 INCLUSIONS AND EXCLUSIONS
1.4.1 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key industry insights
2.2.2.3 Key data from primary sources
2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
2.3.1.2 Approach 2: Based on cost of goods sold & component share
2.3.1.3 Approach 3: Primary interviews
2.3.1.4 Growth forecast
2.3.1.5 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.5.1 STUDY-RELATED ASSUMPTIONS
2.5.2 PARAMETRIC ASSUMPTIONS
2.5.3 GROWTH RATE ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 LATERAL FLOW ASSAY (LFA) COMPONENTS MARKET OVERVIEW
4.2 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PRODUCT AND COUNTRY
4.3 LATERAL FLOW ASSAY COMPONENTS MARKET, BY KEY COUNTRY
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET, REGIONAL MIX, 2025 VS. 2030

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 High prevalence of infectious diseases
5.2.1.2 Rise in geriatric population
5.2.1.3 Growing use of home-based tests driving consumption of components
5.2.1.4 Growing demand for POC testing
5.2.2 RESTRAINTS
5.2.2.1 Inconsistent performance of LFAs impacting demand for components
5.2.2.2 Alternative diagnostic technologies
5.2.3 OPPORTUNITIES
5.2.3.1 Expanding applications driving demand for LFA components
5.2.3.2 Rising demand for LFA components in food & beverage industry
5.2.4 CHALLENGES
5.2.4.1 Limited reimbursements
5.2.4.2 Need for specialized storage and shipping for LFA components
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF LATERAL FLOW ASSAY COMPONENTS, BY KEY PLAYERS, 2023-2025
5.4.2 AVERAGE SELLING PRICE TREND OF LATERAL FLOW ASSAY COMPONENTS, BY REGION, 2023-2025
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Membrane technology
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Lyophilization
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Enzyme-linked immunosorbent assays
5.10 PATENT ANALYSIS
5.10.1 LIST OF MAJOR PATENTS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA (HS CODE 382200)
5.11.2 EXPORT DATA (HS CODE 382200)
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 REGULATORY LANDSCAPE
5.13.1 REGULATORY ANALYSIS
5.13.1.1 North America
5.13.1.2 Europe
5.13.1.3 Asia Pacific
5.13.1.3.1 India
5.13.1.3.2 China
5.13.1.3.3 Japan
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13.2.1 North America
5.13.2.2 Europe
5.13.2.3 Asia Pacific
5.13.2.4 Latin America
5.13.2.5 Rest of the World
5.14 PORTER'S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTES
5.14.3 BARGAINING POWER OF BUYERS
5.14.4 BARGAINING POWER OF SUPPLIERS
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 IMPACT OF AI ON LATERAL FLOW ASSAY COMPONENTS MARKET
5.16.1 INTRODUCTION
5.16.2 POTENTIAL OF AI IN LATERAL FLOW ASSAY COMPONENTS MARKET
5.16.3 AI USE CASES
5.16.4 FUTURE OF AI IN LATERAL FLOW ASSAY COMPONENTS MARKET
5.17 IMPACT OF 2025 US TARIFFS
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 KEY IMPACTS ON REGIONS
5.17.4.1 North America
5.17.4.2 Europe
5.17.4.3 Asia Pacific
5.17.5 IMPACT ON END-USE INDUSTRIES
5.17.5.1 Medical device manufacturing companies

6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 MEMBRANES
6.2.1 NITROCELLULOSE MEMBRANES
6.2.1.1 High protein-binding affinity to drive growth
6.2.2 OTHER MEMBRANES
6.3 PADS
6.3.1 SAMPLE PADS
6.3.1.1 Role of sample pads in ensuring even and controlled sample distribution to drive growth
6.3.2 CONJUGATE PADS
6.3.2.1 Conjugate pads as key performance controllers in lateral flow immunoassays to drive growth
6.3.3 ABSORBENT PADS
6.3.3.1 Absorbent pads as critical backflow preventers in l ateral flow immunoassays to drive growth
6.4 OTHERS

7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE
7.1 INTRODUCTION
7.2 SANDWICH ASSAYS
7.2.1 SUPERIOR SENSITIVITY AND SPECIFICITY TO DRIVE DEMAND
7.3 COMPETITIVE ASSAYS
7.3.1 LOWER SENSITIVITY OF COMPETITIVE ASSAYS COMPARED TO SANDWICH FORMATS TO LIMIT GROWTH
7.4 MULTIPLEX DETECTION ASSAYS
7.4.1 ADOPTION OF MULTI-ANALYTE ASSAYS TO DRIVE GROWTH

8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 CLINICAL TESTING
8.2.1 INFECTIOUS DISEASE TESTING
8.2.1.1 Rising demand in emerging markets to drive growth
8.2.2 CARDIAC MARKER TESTING
8.2.2.1 Cardiovascular disease prevalence to drive demand
8.2.3 PREGNANCY & FERTILITY TESTING
8.2.3.1 Lifestyle changes and rising infertility rates to fuel demand
8.2.4 CHOLESTEROL TESTING/LIPID PROFILING
8.2.4.1 Growing prevalence of obesity and cardiovascular diseases to drive demand
8.2.5 DRUG-OF-ABUSE TESTING
8.2.5.1 Technological advancements and workplace testing initiatives to fuel growth
8.2.6 OTHER CLINICAL TESTING APPLICATIONS
8.3 VETERINARY DIAGNOSTICS
8.3.1 INFECTIOUS DISEASE OUTBREAKS IN LARGE LIVESTOCK ANIMALS TO DRIVE DEMAND
8.4 FOOD SAFETY & ENVIRONMENTAL TESTING
8.4.1 HIGH SENSITIVITY AND EASE OF USE TO FUEL DEMAND FOR LATERAL FLOW ASSAYS IN FOOD SAFETY
8.5 DRUG DEVELOPMENT & QUALITY TESTING
8.5.1 RISING EMPHASIS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE GROWTH

9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER
9.1 INTRODUCTION
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES
9.2.1 RISING POINT-OF-CARE TESTING TO BOOST ADOPTION
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES
9.3.1 GROWING FOCUS ON FAST AND EARLY DIAGNOSIS TO DRIVE GROWTH

10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK
10.2.2 US
10.2.2.1 Expanding patient base and healthcare needs to drive demand
10.2.3 CANADA
10.2.3.1 Research funding and policy support to drive demand
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK
10.3.2 GERMANY
10.3.2.1 Rising point-of-care testing to drive growth
10.3.3 FRANCE
10.3.3.1 Aging population and healthcare policies shaping demand for LFA components
10.3.4 UK
10.3.4.1 Rising burden of chronic conditions to drive demand
10.3.5 ITALY
10.3.5.1 Decentralization of healthcare services to support demand
10.3.6 SPAIN
10.3.6.1 Aging demographics and strong healthcare system to fuel demand
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK
10.4.2 CHINA
10.4.2.1 Modernized healthcare system to drive market
10.4.3 JAPAN
10.4.3.1 Aging population and advanced healthcare system to fuel demand
10.4.4 INDIA
10.4.4.1 Growing base of local manufacturers to drive market
10.4.5 AUSTRALIA
10.4.5.1 Rising infectious disease burden and healthcare spending to drive market
10.4.6 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK
10.5.2 BRAZIL
10.5.2.1 Growing healthcare investments and aging population to drive market
10.5.3 MEXICO
10.5.3.1 Expanding healthcare access and rising chronic disease burden to drive demand
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 EXPANDING HEALTHCARE BUDGETS TO DRIVE GROWTH
10.6.2 MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2024
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LATERAL FLOW ASSAY COMPONENTS MARKET
11.3 REVENUE ANALYSIS, 2022-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Product footprint
11.5.5.4 Application footprint
11.5.5.5 Technique footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 List of key startups/SMEs
11.6.5.2 Competitive benchmarking of key startups/SMEs
11.7 COMPANY VALUATION AND FINANCIAL METRICS
11.7.1 COMPANY VALUATION
11.7.2 FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 EXPANSIONS
11.9.2 OTHER DEVELOPMENTS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 DANAHER CORPORATION
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Expansions
12.1.1.3.2 Others
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses and competitive threats
12.1.2 SARTORIUS AG
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 MnM view
12.1.2.3.1 Key strengths
12.1.2.3.2 Strategic choices
12.1.2.3.3 Weaknesses and competitive threats
12.1.3 AHLSTROM
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 MnM view
12.1.3.3.1 Key strengths
12.1.3.3.2 Strategic choices
12.1.3.3.3 Weaknesses and competitive threats
12.1.4 MERCK KGAA
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 Recent developments
12.1.4.3.1 Expansions
12.1.5 ADVANCED MICRODEVICES PVT. LTD.
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.6 DCN DIAGNOSTICS
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 FORTIS LIFE SCIENCES, LLC.
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.8 COBETTER
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.9 AXIVA SICHEM PVT. LTD.
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 NUPORE FILTRATION SYSTEMS
12.1.10.1 Business overview
12.1.10.2 Products offered
12.2 OTHER PLAYERS
12.2.1 BALLYA
12.2.2 EQUINOX
12.2.3 CYTODIAGNOSTICS INC
12.2.4 POREX
12.2.5 KENOSHA
12.2.6 ANTITECK LIFE SCIENCES LIMITED
12.2.7 MINIPORE MICRO PRODUCTS
12.2.8 PRAHAS HEALTHCARE
12.2.9 NANOHYBRIDS
12.2.10 PROGNOSIS BIOTECH S.A.
12.2.11 LATERAL DX
12.2.12 BANGS LABORATORIES
12.2.13 BBI SOLUTIONS
12.2.14 SONA NANOTECH
12.2.15 ZHEJIANG TAILIN BIOENGINEERING CO., LTD.

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS